{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T10:01:18Z","timestamp":1791021678452,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","award":["04-078-0080"],"award-info":[{"award-number":["04-078-0080"]}],"id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012351","name":"Mitsubishi Tanabe Pharma Corporation","doi-asserted-by":"publisher","award":["-078-0080"],"award-info":[{"award-number":["-078-0080"]}],"id":[{"id":"10.13039\/501100012351","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytokine"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.cyto.2024.156534","type":"journal-article","created":{"date-parts":[[2024,2,13]],"date-time":"2024-02-13T00:28:19Z","timestamp":1707784099000},"page":"156534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Th17\/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH"],"prefix":"10.1016","volume":"176","author":[{"given":"Noriyasu","family":"Seki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideto","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhei","family":"Tanemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Ishigaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Takei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunio","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Yoshimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsutomu","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.cyto.2024.156534_b0005","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/annrheumdis-2011-200742","article-title":"Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database","volume":"71","author":"Meier","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.cyto.2024.156534_b0010","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J. Clin. Invest."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0015","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1136\/ard.62.11.1088","article-title":"Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach","volume":"62","author":"Mukerjee","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"12","key":"10.1016\/j.cyto.2024.156534_b0020","doi-asserted-by":"crossref","first-page":"3792","DOI":"10.1002\/art.21433","article-title":"Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study","volume":"52","author":"Hachulla","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.cyto.2024.156534_b0025","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.10775","article-title":"Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement","volume":"48","author":"Steen","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.cyto.2024.156534_b0030","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/BOR.0b013e3282ec67d4","article-title":"Screening and therapy of pulmonary hypertension in systemic sclerosis","volume":"19","author":"Bull","year":"2007","journal-title":"Curr Opin Rheumatol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156534_b0035","doi-asserted-by":"crossref","first-page":"e12106","DOI":"10.1371\/journal.pone.0012106","article-title":"Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular Injury","volume":"5","author":"Pendergrass","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0040","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13075-022-02734-9","article-title":"Cytokine signatures differentiate systemic sclerosis patients at high versus low risk for pulmonary arterial hypertension","volume":"24","author":"Kolstad","year":"2022","journal-title":"Arthritis Res. Ther."},{"issue":"4","key":"10.1016\/j.cyto.2024.156534_b0045","first-page":"274","article-title":"Serum cytokines and their predictive value in pulmonary involvement of systemic sclerosis","volume":"36","author":"Becker","year":"2019","journal-title":"Sarcoidosis Vasc. Diffuse Lung Dis."},{"key":"10.1016\/j.cyto.2024.156534_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2023.156183","article-title":"A comparative study of modulatory interaction between cytokines and apoptotic proteins among Scleroderma patients with and without pulmonary involvement","volume":"166","author":"Khadilkar","year":"2023","journal-title":"Cytokine"},{"issue":"8","key":"10.1016\/j.cyto.2024.156534_b0055","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1136\/ard.2004.027094","article-title":"Early T cell activation in the skin from patients with systemic sclerosis","volume":"64","author":"Kalogerou","year":"2005","journal-title":"Ann. Rheum. Dis."},{"issue":"9","key":"10.1016\/j.cyto.2024.156534_b0060","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","article-title":"T cells in systemic sclerosis: a reappraisal","volume":"51","author":"O\u2019Reilly","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.cyto.2024.156534_b0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ncprheum0618","article-title":"Possible implication of the effector CD4+ T-cell subpopulation Th17 in the pathogenesis of systemic scleroderma","volume":"3","author":"Deleuran","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0070","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2249.2007.03356.x","article-title":"Lord, The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease","volume":"148","author":"Afzali","year":"2007","journal-title":"Clin. Exp. Immunol."},{"issue":"9","key":"10.1016\/j.cyto.2024.156534_b0075","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00296-011-2056-y","article-title":"Th17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study","volume":"32","author":"Rodriguez-Reyna","year":"2012","journal-title":"Rheumatol. Int."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0080","doi-asserted-by":"crossref","first-page":"R4","DOI":"10.1186\/ar4430","article-title":"MLi, Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction","volume":"16","author":"Yang","year":"2014","journal-title":"Arthritis. Res. Ther."},{"key":"10.1016\/j.cyto.2024.156534_b0085","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2018.09.037","article-title":"Imbalance between T helper 17 and regulatory T cell subsets plays a significant role in the pathogenesis of systemic sclerosis","volume":"108","author":"Mo","year":"2018","journal-title":"Biomed. Pharmacother."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0090","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1002\/1529-0131(200011)43:11<2455::AID-ANR12>3.0.CO;2-K","article-title":"Increased interleukin-17 production in patients with systemic sclerosis","volume":"43","author":"Kurasawa","year":"2000","journal-title":"Arthrits. Rheum."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0095","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ni1254","article-title":"Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages","volume":"6","author":"Harrington","year":"2005","journal-title":"Nat. Immunol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156534_b0100","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1084\/jem.20061308","article-title":"Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides","volume":"203","author":"Liang","year":"2006","journal-title":"J. Exp. Med."},{"issue":"7152","key":"10.1016\/j.cyto.2024.156534_b0105","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nature05970","article-title":"IL-21 initiates an alternative pathway to induce proinflammatory TH17 cells","volume":"448","author":"Korn","year":"2007","journal-title":"Nature"},{"issue":"7128","key":"10.1016\/j.cyto.2024.156534_b0110","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a TH17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.cyto.2024.156534_b0115","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1038\/ni1497","article-title":"Development, cytokine profile and function of human interleukin 17-producing helper T cells","volume":"8","author":"Wilson","year":"2007","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.cyto.2024.156534_b0120","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1146\/annurev.immunol.021908.132710","article-title":"IL-17 and Th17 cells","volume":"27","author":"Korn","year":"2009","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.cyto.2024.156534_b0125","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/968549","article-title":"Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases","volume":"2013","author":"Qu","year":"2013","journal-title":"Clin. Dev. Immunol."},{"issue":"8","key":"10.1016\/j.cyto.2024.156534_b0130","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family Nat","volume":"9","author":"Gaffen","year":"2009","journal-title":"Rev. Immunol."},{"issue":"4","key":"10.1016\/j.cyto.2024.156534_b0135","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.4049\/jimmunol.181.4.2799","article-title":"The human IL-17F\/IL-17A heterodimeric cytokine signals through the IL-17RA\/IL-17RC receptor complex","volume":"181","author":"Wright","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0140","doi-asserted-by":"crossref","first-page":"8906","DOI":"10.1038\/s41598-017-08360-9","article-title":"The human IL-17A\/F heterodimer: a two-faced cytokine with unique receptor recognition properties","volume":"7","author":"Goepfert","year":"2017","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0145","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative","volume":"72","author":"van den Hoogen","year":"2013","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0150","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"Galie","year":"2016","journal-title":"Eur. Heart J."},{"issue":"7","key":"10.1016\/j.cyto.2024.156534_b0155","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/annrheumdis-2013-203301","article-title":"Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study","volume":"73","author":"Coghlan","year":"2014","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0160","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis","volume":"177","author":"Goh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0165","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.jacc.2016.12.037","article-title":"A test in context: E\/A and E\/e' to assess diastolic dysfunction and LV filling pressure","volume":"69","author":"Mitter","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.cyto.2024.156534_b0170","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1002\/cyto.a.20623","article-title":"MIFlowCyt: the minimum information about a flow cytometry experiment","volume":"73","author":"Lee","year":"2008","journal-title":"Cytometry A"},{"issue":"3","key":"10.1016\/j.cyto.2024.156534_b0175","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.cyto.2024.156534_b0180","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res. Ther."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0185","first-page":"44","article-title":"IL-17, IL-6 and IFN-\u03b3 in systemic sclerosis patients","volume":"53","author":"B\u0103l\u0103nescu","year":"2015","journal-title":"Rom. J. Intern. Med."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0190","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1093\/rheumatology\/keac136","article-title":"Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan","volume":"61","author":"Isomura","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"10.1016\/j.cyto.2024.156534_b0195","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12016-021-08891-0","article-title":"Therapeutic approaches to systemic sclerosis: Recent approvals and future candidate therapies","volume":"64","author":"Lescoat","year":"2021","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"11","key":"10.1016\/j.cyto.2024.156534_b0200","doi-asserted-by":"crossref","first-page":"6086","DOI":"10.1111\/jocd.15133","article-title":"Peripheral blood IL-6 levels in systemic sclerosis patients: Correlation between IL-6 levels and clinical phenotypes","volume":"21","author":"Lin","year":"2022","journal-title":"J. Cosmet. Dermatol."},{"issue":"3","key":"10.1016\/j.cyto.2024.156534_b0205","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1002\/art.30159","article-title":"Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension","volume":"63","author":"Hsu","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"4","key":"10.1016\/j.cyto.2024.156534_b0210","doi-asserted-by":"crossref","DOI":"10.1088\/1752-7155\/10\/4\/046013","article-title":"Th-17 cytokines and interstitial lung involvement in systemic sclerosis","volume":"10","author":"Rolla","year":"2016","journal-title":"J. Breath. Res."},{"issue":"2","key":"10.1016\/j.cyto.2024.156534_b0215","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"12","key":"10.1016\/j.cyto.2024.156534_b0220","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1093\/rheumatology\/keq275","article-title":"The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab","volume":"49","author":"Shima","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"10038","key":"10.1016\/j.cyto.2024.156534_b0225","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.cyto.2024.156534_b0230","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir. Med."},{"issue":"1","key":"10.1016\/j.cyto.2024.156534_b0235","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1378\/chest.06-0682","article-title":"Endothelin-1\/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension","volume":"131","author":"Montani","year":"2007","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.cyto.2024.156534_b0240","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.pharmthera.2013.10.002","article-title":"Targeted therapies in pulmonary arterial hypertension","volume":"141","author":"Montani","year":"2014","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.cyto.2024.156534_b0245","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jid.2019.08.438","article-title":"IL-17A induces endothelin-1 expression through p38 pathway in prurigo nodularis","volume":"140","author":"Wong","year":"2020","journal-title":"J. Invest. Dermatol."},{"issue":"2","key":"10.1016\/j.cyto.2024.156534_b0250","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.lfs.2014.01.084","article-title":"Endothelin regulates function of IL-17-producing T cell subset","volume":"118","author":"Tanaka","year":"2014","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.cyto.2024.156534_b0255","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/rccm.201507-1398OC","article-title":"Ambrisentan and tadalafil up-front combination therapy in scleroderma-associated pulmonary arterial hypertension","volume":"192","author":"Hassoun","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."}],"container-title":["Cytokine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043466624000371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T10:30:18Z","timestamp":1778581818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043466624000371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":51,"alternative-id":["S1043466624000371"],"URL":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156534","relation":{},"ISSN":["1043-4666"],"issn-type":[{"value":"1043-4666","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Th17\/IL-17A axis is critical for pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc): SSc patients with high levels of serum IL-17A exhibit reduced lung functions and increased prevalence of PAH","name":"articletitle","label":"Article Title"},{"value":"Cytokine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cyto.2024.156534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"156534"}}